CJC-1295 + Ipamorelin: GH Optimization
A foundational growth hormone secretagogue stack pairing a GHRH analogue (CJC-1295) with a selective GH secretagogue (Ipamorelin). CJC-1295 amplifies GH output by extending GHRH signal duration, while Ipamorelin triggers additional GH pulses through the ghrelin receptor with minimal cortisol or prolactin elevation. Together they produce synergistic, more physiologically natural GH release compared to either peptide alone.
Safety Notes
Both peptides are unapproved research compounds that stimulate endogenous growth hormone release. Contraindicated in individuals with active or suspected hormone-sensitive malignancies. Potential side effects include water retention, joint discomfort, and changes in insulin sensitivity consistent with elevated GH. Not for use during pregnancy or breastfeeding.
Peptides in This Stack
- 1CJC-1295Fat Loss
Acts as the long-acting GHRH analogue backbone of the stack, extending natural GH pulse duration and amplitude through its DAC modification. Its sustained activity makes it the primary driver of elevated GH output across the dosing window.
- 2IpamorelinPerformance
A highly selective ghrelin receptor agonist that triggers additional GH pulses with negligible cortisol or prolactin co-stimulation, making it the cleanest available complement to a GHRH analogue. It synergises with CJC-1295 by activating GH release through an entirely distinct receptor pathway.
Research References
Emerging
- Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adultsJ Clin Endocrinol Metab 2006 · PMID 16822960
- Ipamorelin, the first selective growth hormone secretagogueEur J Endocrinol 1998 · PMID 9849822
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.